Proactive Investors - Run By Investors For Investors

Zelda Therapeutics responds to ASX query on price and volume increases

The Australian bio-pharmaceutical company is developing proprietary cannabinoid formulations to treat a variety of medical conditions.
shares rising chart
A clinical trial to assess the efficacy of cannabis in reducing opioid dependence has started

Zelda Therapeutics Ltd (ASX:ZLD) was queried by the ASX yesterday relating to the price of its securities, which went from a low of 4.6 cents at the close of trading on July 8 to a high of 6.7 cents yesterday, July 10.

The ASX also noted the increase in the volume of Zelda’s securities traded during the same period.

Zelda responded to the query explaining that it was not aware of any information that had not been released to market which, if known by some in the market, could explain the recent trading in its securities.

The company also reconfirmed that it recently received formal approval for its Phase I Opioid Reduction Trial from the St Vincent’s Hospital Ethics and Governance Committees.

READ: Zelda Therapeutics to begin opioid reduction trial with approval granted

The Phase I trial will evaluate the safety and tolerability of whole plant extract following single and repeated doses in nine patients with chronic non-cancer pain on long-term opioid analgesia.

Secondary outcomes include pharmacokinetics and the effects on pain, mood, sleep and opioid use over the duration of the trial.

The Phase I trial has commenced with preliminary results expected by late Q3 2019 and final results in Q4 2019, which is similar to the timeframe the company expects to report on its ongoing Phase II Insomnia trial.

Zelda’s CEO has also continued to make presentations in relation to the company’s business and its objectives, which have been well attended by investors.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

Related Articles

cannabis leaf
May 08 2019
The company plans to leverage its portfolio of brands as well as its distribution network of more than 39,000 European pharmacies to maximize margins and profitability
FSD Pharma facility
June 11 2019
The indoor hydroponic facility will be optimized for large-scale, medical-grade cannabis production and once complete, is expected to have over 3.9 million sq/ft available for production
June 18 2019
The cannabis company's strategy is to focus solely on the massive California market, where it plans to establish a network of dispensaries with owner-operators
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use